Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,006.34
    -65.29 (-1.29%)
     

  • Dow

    37,927.90
    -533.02 (-1.39%)
     

  • Nasdaq

    15,417.53
    -295.22 (-1.88%)
     

  • Bitcoin USD

    63,373.15
    -2,844.06 (-4.30%)
     

  • CMC Crypto 200

    1,347.14
    -35.44 (-2.56%)
     

  • FTSE 100

    8,051.82
    +11.44 (+0.14%)
     

  • Gold

    2,331.60
    -6.80 (-0.29%)
     

  • Crude Oil

    82.69
    -0.12 (-0.14%)
     

  • 10-Yr Bond

    4.7290
    +0.0770 (+1.66%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Analysts Rate Voyager Therapeutics and Its Peers in April

Kenneth Smith
Updated
Analysts Rate Voyager Therapeutics and Its Peers in April

Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.

Continue reading